Biotransplant(BTRN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN)

BTRN 35.09

-1.4%

Nov 4 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: seminole who wrote (1270)	3/15/2002 3:08:18 PM
From: scaram(o)uche	Read Replies (1) of 1475

grrrrrrr............ messages.yahoo.com I've tried for years to get reasonable answers. Let's try this........ Jim Young: Your own scientists (Branco et al.) have described a mechanism for 507 where antigen-specific, activated T cells were selectively depleted in vitro. Your own intravenous studies in humans have shown that non-depleting concentrations of MAb were as effective as depleting concentrations. Given that the results of Dumont et al. are aged about 5 years and that you had extensive in vivo experience with BTI-322, can you understand why I feel that you're a frigging jerk? Clearly explain, in a public forum, why you would choose to put patients at risk for immunosuppression when the casual observer begs for prolonged low dose testing. Easy? Explain in public, and flip flop the situation..... make ME look like the fool. I'll be happy (and perhaps richer) for it. In the course of any explanation, you're going to have to cover the design of (and results derived from) your small, tiny, little itsy bitsy, stooooooooopid intravenous phase II trial. Were Branco et al. wrong? Has MEDI published a manuscript where the results should be withdrawn, formally? Thank you.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next